News
TVTX
19.19
+1.05%
0.20
BRIEF-Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters · 11/16 22:54
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease. SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., the IgA Nephropathy Foundation, ...
GlobeNewswire · 11/15 13:00
Travere Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga · 11/03 13:57
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Benzinga · 11/01 20:01
BRIEF-Adage Capital Partners Gp, L.L.C. Reports 6.14% Passive Stake In Travere Therapeutics Inc As Of October 18 - SEC Filing
Reuters · 10/28 20:39
Aeglea BioTherapeutics upgraded to overweight at Wells Fargo on pegtarviliase optimism
Seekingalpha · 10/28 13:30
Travere Therapeutics Q3 Non-GAAP Loss Widens as Revenue Falls
Travere Therapeutics Q3 Non-GAAP Loss Widens as Revenue Falls
MT Newswires · 10/28 10:49
Recap: Travere Therapeutics Q3 Earnings
Benzinga · 10/27 20:49
BRIEF-Travere Therapeutics Reports Third Quarter 2022 Financial Results
Reuters · 10/27 20:36
Travere Therapeutics GAAP EPS of -$1.09 misses by $0.17, revenue of $53.5M misses by $1.26M
Seekingalpha · 10/27 20:08
Travere Therapeutics Q3 Adj. EPS $(0.76) Beats $(0.89) Estimate, Sales $53.50M Miss $54.76M Estimate
Benzinga · 10/27 20:04
-- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Reports Q3 Revenue $53.5M, vs. Street Est of $54.8M
-- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Reports Q3 Revenue $53.5M, vs. Street Est of $54.8M
MT Newswires · 10/27 16:18
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
Data support the Company’s lead investigational product candidate sparsentanSAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present data from its sparsentan ...
GlobeNewswire · 10/26 20:30
Earnings Outlook For Travere Therapeutics
Benzinga · 10/26 19:32
Travere Therapeutics to Report Third Quarter 2022 Financial Results
SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022, after the close of the U.S. financial markets. The Company will host a...
GlobeNewswire · 10/20 20:30
SVB Leerink Maintains Outperform on Travere Therapeutics, Lowers Price Target to $38
Benzinga · 10/20 15:41
--SVB Securities Adjusts Travere Therapeutics' Price Target to $38 from $45, Keeps Outperform Rating
--SVB Securities Adjusts Travere Therapeutics' Price Target to $38 from $45, Keeps Outperform Rating
MT Newswires · 10/20 13:24
--HC Wainwright Adjusts Price Target on Travere Therapeutics to $36 From $42, Maintains Buy Rating
--HC Wainwright Adjusts Price Target on Travere Therapeutics to $36 From $42, Maintains Buy Rating
MT Newswires · 10/20 12:29
HC Wainwright Adjusts Travere Therapeutics' Price Target to $36 from $42, Maintains Buy Rating
HC Wainwright Adjusts Travere Therapeutics' Price Target to $36 from $42, Maintains Buy Rating
MT Newswires · 10/17 11:27
More
Webull provides a variety of real-time TVTX stock news. You can receive the latest news about Travere Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. It is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker.